Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice

Neuroscience Letters

Volumn 436, Issue 2, 2008, Pages 269-272

  Uz, Tolga ^a   Dimitrijevic, Nikola ^a   Imbesi, Marta ^a   Manev, Hari ^a   Manev, Radmila ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

5 Lipoxygenase (5 LOX, 5LO); Antidepressant; Atherosclerosis; Cardiovascular; Depression; GluR1

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLIMBING; CONTROLLED STUDY; DRUG EFFECT; ENZYME DEFICIENCY; FORCED SWIMMING TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REST;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; INDOLES; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, TRANSGENIC; MOVEMENT; SWIMMING; TIME FACTORS;

EID: 41949100044     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.03.041     Document Type: Article

References (29)

1. Cassano P., Hidalgo A., Burgos V., Adris S., and Argibay P. Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). Pharmacogenomics J. 6 (2006) 381-387
2. Chinnici C.M., Yao Y., and Praticò D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol. Aging 28 (2007) 1457-1462
3. Ciceri P., Rabuffetti M., Monopoli A., and Nicosia S. Production of leukotrienes in a model of focal cerebral ischaemia in the rat. Br. J. Pharmacol. 133 (2001) 1323-1329
4. Detke M.J., and Lucki I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav. Brain Res. 73 (1996) 43-46
5. Du J., Suzuki K., Wei Y., Wang Y., Blumenthal R., Chen Z., Falke C., Zarate Jr. C.A., and Manji H.K. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32 (2007) 793-802
6. Fang S.H., Zhou Y., Chu L.S., Zhang W.P., Wang M.L., Yu G.L., Peng F., and Wei E.Q. Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia. Neurosci. Lett. 412 (2007) 78-83
7. Faramawi M.F., Gustat J., Wildman R.P., Rice J., Johnson E., and Sherwin R. Relation between depressive symptoms and common carotid artery atherosclerosis in American persons ≤65 years of age. Am. J. Cardiol. 99 (2007) 1610-1613
8. Firuzi O., Zhuo J., Chinnici C.M., Wisniewski T., and Praticò D. 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease. FASEB J. (2007) (Epub ahead of print)
9. Fischer L., Hornig M., Pergola C., Meindl N., Franke L., Tanrikulu Y., Dodt G., Schneider G., Steinhilber D., and Werz O. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br. J. Pharmacol. 152 (2007) 471-480
10. +-ATPase activity. Biochem. Biophys. Res. Commun. 235 (1997) 374-376
11. Hirano S., Miyata S., Onodera K., and Kamei J. Involvement of dopamine D1 receptors and alpha1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test. Eur. J. Pharmacol. 562 (2007) 72-76
12. Imbesi M., Zavoreo I., Uz T., Sharma R.P., Dimitrijevic N., Manev H., and Manev R. 5-Lipoxygenase inhibitor MK-886 increases GluR1 phosphorylation in neuronal cultures in vitro and in the mouse cortex in vivo. Brain Res. 1147 (2007) 148-153
13. Jawien J., Gajda M., Rudling M., Mateuszuk L., Olszanecki R., Guzik T.J., Cichocki T., Chlopicki S., and Korbut R. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 36 (2006) 141-146
14. Kurtuncu M., Luka L.J., Dimitrijevic N., Uz T., and Manev H. Reliability assessment of an automated forced swim test device using two mouse strains. J. Neurosci. Methods 149 (2005) 26-30
15. Kurtuncu M., Battista N., Uz T., D'Agostino A., Dimitrijevic N., Pasquariello N., Manev R., Maccarrone M., and Manev H. Effects of cocaine in 5-lipoxygenase-deficient mice. J. Neural Transm. 115 (2008) 389-395
16. Lötzer K., Funk C.D., and Habenicht A.J. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim. Biophys. Acta 1736 (2005) 30-37
17. Lötzer K., Jahn S., Kramer C., Hildner M., Nüsing R., Funk C.D., and Habenicht A.J. 5-Lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells. Prostaglandins Other Lipid Mediat. 84 (2007) 108-115
18. Maeng S., Zarate Jr. C.A., Du J., Schloesser R.J., McCammon J., Chen G., and Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63 (2008) 349-352
19. Manev H., and Manev R. 5-Lipoxygenase as a possible biological link between depressive symptoms and atherosclerosis. Arch. Gen. Psychiatry 64 (2007) 1333
20. Manev R., Mrazovac D., and Manev H. Possible role for interactions between 5-lipoxygenase (5-LOX) and AMPA GluR1 receptors in depression and in antidepressant therapy. Med. Hypotheses 69 (2007) 1076-1079
21. Martínez-Turrillas R., Del Río J., and Frechilla D. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem. Biophys. Res. Commun. 353 (2007) 750-755
22. Mayburd A.L., Martlínez A., Sackett D., Liu H., Shih J., Tauler J., Avis I., and Mulshine J.L. Ingenuity network-assisted transcription profiling: identification of a new pharmacologic mechanism for MK886. Clin. Cancer Res. 12 (2006) 1820-1827
23. Ménard C., Valastro B., Martel M.A., Chartier E., Marineau A., Baudry M., and Massicotte G. AMPA receptor phosphorylation is selectively regulated by constitutive phospholipase A(2) and 5-lipoxygenase activities. Hippocampus 15 (2005) 370-380
24. Müller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Müller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Möller H.J., Arolt V., and Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 11 (2006) 680-684
25. Rådmark O., and Samuelsson B. 5-Lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat. 83 (2007) 162-174
26. Stewart J.C., Janicki D.L., Muldoon M.F., Sutton-Tyrrell K., and Kamarck T.W. Negative emotions and 3-year progression of subclinical atherosclerosis. Arch. Gen. Psychiatry 64 (2007) 225-233
27. Swayze R.D., Lisé M.F., Levinson J.N., Phillips A., and El-Husseini A. Modulation of dopamine mediated phosphorylation of AMPA receptors by PSD-95 and AKAP79/150. Neuropharmacology 47 (2004) 764-778
28. Uz T., Dwivedi Y., Savani P.D., Impagnatiello F., Pandey G., and Manev H. Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. J. Neurochem. 73 (1999) 693-699
29. Zhang W.P., Hu H., Zhang L., Ding W., Yao H.T., Chen K.D., Sheng W.W., Chen Z., and Wei E.Q. Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci. Lett. 363 (2004) 247-251